LINCOLN.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 05:59):

Stats
Today's Volume	36 823.00
Average Volume	94 898.00
Market Cap	11.05B
EPS	INR0 ( 2024-02-08 )
Next earnings date	( INR0 ) 2024-05-22
Last Dividend	INR1.500 ( 2023-09-15 )
Next Dividend	INR0 ( N/A )
P/E	12.66
ATR14	INR1.381 (0.25%)

Volume Correlation

Long: -0.37 (neutral)

Short: -0.58 (weak negative)

Signal:(46.135) Neutral

Lincoln Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lincoln Pharmaceuticals Correlation - Currency/Commodity

0.32
( neutral )

0.07
( neutral )

0.32
( neutral )

-0.39
( neutral )

-0.47
( neutral )

-0.67
( moderate negative )

Lincoln Pharmaceuticals Financials

Annual	2022
Revenue:	INR5.10B
Gross Profit:	INR2.69B (52.70 %)
EPS:	INR36.40

FY	2022
Revenue:	INR5.10B
Gross Profit:	INR2.69B (52.70 %)
EPS:	INR36.40

FY	2022
Revenue:	INR4.68B
Gross Profit:	INR2.48B (53.06 %)
EPS:	INR34.63

FY	2021
Revenue:	INR4.15B
Gross Profit:	INR2.16B (52.05 %)
EPS:	INR31.11

Financial Reports:

No articles found.

Lincoln Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR1.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Lincoln Pharmaceuticals Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.60 - low (52.89%) | Divividend Growth Potential Score: 5.23 - Stable (4.67%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR1.000	2016-09-23
Last Dividend	INR1.500	2023-09-15
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	INR11.20	--
Avg. Dividend % Per Year	0.32%	--
Score	2.19	--
Div. Sustainability Score	4.60
Div.Growth Potential Score	5.23
Div. Directional Score	4.92	--

Next Divdend (Est)
(2024-06-25)

INR1.526 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.19

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR1.500	0.67%
2019	INR1.500	0.66%
2020	INR1.500	0.73%
2021	INR1.500	0.62%
2022	INR1.500	0.41%
2023	INR1.500	0.42%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
RPPL.NS	Dividend Junior	2023-08-24	Annually	6	0.31%
LICHSGFIN.NS	Dividend Junior	2023-08-18	Annually	23	1.85%
GANDHITUBE.NS	Dividend Junior	2023-07-28	Annually	17	1.82%
APOLSINHOT.NS	Dividend Junior	2023-09-22	Annually	10	0.11%
TECHNOE.NS	Dividend Junior	2023-09-15	Annually	16	1.13%
OMINFRAL.NS	Dividend Junior	2023-09-22	Annually	13	0.78%
INTENTECH.NS	Dividend Junior	2023-09-21	Annually	6	0.44%
COROMANDEL.NS	Dividend Knight	2023-07-13	Annually	19	1.02%
SHANTIGEAR.NS	Dividend Junior	2023-07-11	Annually	23	1.02%
MANALIPETC.NS	Dividend Junior	2023-09-15	Annually	18	1.50%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.159	1.500	6.83	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.166	1.500	9.26	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	47.50	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	10.34	2.00	6.55	10.00	[0 - 30]
freeCashFlowPerShareTTM	10.34	2.00	4.83	9.66	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.487	1.000	5.22	5.22	[0.2 - 0.8]
operatingProfitMarginTTM	0.182	1.000	8.35	8.35	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.60

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.06	1.000	8.78	0	[1 - 100]
returnOnEquityTTM	0.166	2.50	9.53	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	10.34	2.00	6.55	9.66	[0 - 30]
dividendYielPercentageTTM	0.264	1.500	3.41	0	[0 - 0.4]
operatingCashFlowPerShareTTM	10.34	2.00	6.55	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.56	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0376	1.000	-1.560	0	[0.1 - 0.5]
Total Score				5.23

Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company's product portfolio includes dermatologist preparations, gynecological products, gastrointestinal ranges, otology products, and phosphodiesterase type 5 inhibitor and general anesthetics. It provides products in the areas of cough and cold, anti-allergic, and anti-asthmatics; sterile ophthalmic eye drops and ointment; anti-malarial; vitamins, minerals, and antioxidants; anti-bacterial, anti-viral, and anti-fungal vitamins; analgesic and anti-pyretic; anti-psychotic, anti-convulsant, anti-depressant, and anti-diabetic; cardiac anti-hypertensives, and diuretic; and anti-diarrheal, anti-spasmodic, and laxative. The company also offers branded generics. Lincoln Pharmaceuticals Limited was founded in 1979 and is based in Ahmedabad, India.